TG Therapeutics, Inc. · TGTX · FY2025 Q1 · Calendar Q2 2025
TG Therapeutics lifts 2025 outlook as BRIUMVI adoption accelerates
The quarter’s reported BRIUMVI sales growth, repeat prescriptions exceeding new prescriptions, and higher 2025 revenue guidance support a positive commercial trajectory. The investment case remains exposed to competition, reliance on BRIUMVI, and execution of planned formulation and pipeline studies.
Research this report with FN2. Free to start; review your question before sending.
Earnings scorecard
Reported versus consensusMarket reaction
prior-close to event-session closeAsk FN2 about TGTX FY2025 Q1
Choose a question to continue your researchFree to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Management reported Q1 U.S. BRIUMVI net sales of $119.7 million, up 137% year over year, and said repeat prescriptions now exceed new prescriptions. It raised 2025 revenue guidance to $560 million. The prior-quarter analysis cited $525 million in FY2025 U.S. revenue guidance; the supplied summaries describe the scopes differently, so they are not directly comparable.
Guidance delta
Management raised FY2025 revenue guidance to $560 million. The previous summary cited $525 million of FY2025 U.S. revenue guidance; supplied information does not establish these as identical measures.
Key takeaways
- BRIUMVI Q1 U.S. net sales were $119.7 million, up 137% year over year.
- Management said repeat prescriptions exceeded new prescriptions, an indicator of persistence.
- FY2025 revenue guidance was raised to $560 million.
- Management described pivotal studies for simplified IV dosing and subcutaneous BRIUMVI as planned.
Management priorities
- Continue BRIUMVI commercial expansion, including hospital infusion-center reach and a direct-to-patient campaign.
- Advance planned pivotal trials of simplified IV dosing and subcutaneous BRIUMVI regimens.
- Progress the planned Phase 1 BRIUMVI study in myasthenia gravis and azer-cel study in progressive MS.
Follow TGTX with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Analyst 52W Price Targets
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 22, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| Evercore ISI Group | Outperform | Outperform | Maintain | Nov 10, 2026 |
| HC Wainwright & Co. | Buy | Buy | Maintain | Sep 1, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Aug 7, 2026 |
| B. Riley Securities | Buy | Buy | Maintain | Jul 27, 2026 |
| B of A Securities | Underperform | Underperform | Maintain | Jul 7, 2026 |
| Goldman Sachs | Neutral | Neutral | Maintain | Jan 15, 2026 |
| Ladenburg Thalmann | Buy | Buy | Maintain | May 2, 2024 |
| Jefferies | Buy | Buy | Maintain | Nov 1, 2023 |
| Cantor Fitzgerald | Overweight | Overweight | Maintain | Feb 7, 2023 |
| HC Wainwright& Co. | Buy | Buy | Maintain | Aug 1, 2021 |
| B. Riley FBR | Buy | Buy | Maintain | Feb 9, 2021 |
| H.C. Wainwright | Buy | Buy | Maintain | Jan 17, 2020 |
| Raymond James | Outperform | Strong Buy | Downgrade | Sep 25, 2018 |
Named analyst price targets
Upside is calculated against the persisted current price $63.34. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| H.C. Wainwright | Emily Bodnar | $78 | $46.17 | +23.1% | Aug 4, 2026 |
| Jefferies | Analyst unavailable | $83 | $54.4 | +31.0% | Jun 22, 2026 |
| H.C. Wainwright | Analyst unavailable | $70 | $39.75 | +10.5% | May 6, 2026 |
| Goldman Sachs | Analyst unavailable | $39 | $29.54 | -38.4% | Jan 15, 2026 |
| H.C. Wainwright | Emily Bodnar | $60 | $36.7 | -5.3% | Oct 6, 2025 |
| H.C. Wainwright | Edward White | $27.5 | $12.93 | -56.6% | Nov 5, 2024 |
| Goldman Sachs | Corinne Jenkins | $20 | $20.58 | -68.4% | Aug 6, 2024 |
| H.C. Wainwright | Edward White | $24.5 | $8.21 | -61.3% | May 3, 2024 |
| Cantor Fitzgerald | Analyst unavailable | $24 | $18.48 | -62.1% | Feb 7, 2023 |
| Evercore ISI | Analyst unavailable | $16 | $11.83 | -74.7% | Dec 30, 2022 |
| H.C. Wainwright | Edward White | $12 | $4.23 | -81.1% | Dec 29, 2022 |
| Goldman Sachs | Analyst unavailable | $5 | $7.26 | -92.1% | Apr 19, 2022 |
| Telsey Advisory | Mayank Mamtani | $11.5 | $3.46 | -81.8% | Apr 18, 2022 |
Track every rating change on TGTX the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationBased in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma.…
Historical context
All TGTX earningsHealthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| ASND Ascendis Pharma A/S | FY2026 Q3 · Calendar Q4 2026 | +38.7% | +3.0% | Ascendis Q3 growth broadens the story, while execution risks remain |
| ALC Alcon Inc. | FY2026 Q3 · Calendar Q4 2026 | +2.2% | -2.3% | Alcon holds FY outlook as new launches meet IOL competition |
Latest beats and misses
Who reports nextBeat on EPS
- INTUFY2027 Q1 · November 19, 2026+18.3% EPS-6.2% move
- ROSTFY2026 Q3 · November 19, 2026+2.1% EPS-2.8% move
- ESTCFY2027 Q2 · November 19, 2026+16.2% EPS+2.0% move
- KEYSFY2026 Q4 · November 19, 2026+7.1% EPS-1.5% move
- WSMFY2026 Q3 · November 19, 20260.0% EPS-15.2% move
- WMGFY2026 Q4 · November 19, 2026+50.9% EPS-0.6% move
Missed on EPS
- NTESFY2026 Q3 · November 19, 2026-12.8% EPS-11.4% move
- FUTUFY2026 Q3 · November 19, 2026-7.8% EPS+4.8% move
- BABAFY2027 Q2 · November 19, 2026-29.2% EPS-1.3% move
- SQMFY2026 Q3 · November 17, 2026-3.0% EPS-5.5% move
- VIKFY2026 Q3 · November 17, 2026-12.6% EPS+4.4% move
- XPFY2026 Q3 · November 16, 2026-3.0% EPS-2.5% move
Get the TGTX recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-05-11T10:29:34.698584+00:00
- FN2 earnings calendar · 2025-04-23T00:02:08.365952+00:00
- Polygon adjusted daily market bars · 2026-11-15T20:00:47.158795+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-15T20:00:47.155995+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-15. For educational purposes only; not investment advice.